A Phase I-II Trial of Daratumumab for the Treatment of Patients With AL Amyloidosis
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Daratumumab (Primary) ; Diphenhydramine; Diphenhydramine; Famotidine; Loratadine; Loratadine; Methylprednisolone; Montelukast; Montelukast; Ondansetron; Paracetamol; Paracetamol
- Indications Amyloid light-chain amyloidosis
- Focus Adverse reactions
- 17 Jul 2020 Status changed from active, no longer recruiting to completed.
- 10 Jul 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Aug 2020.
- 24 Jan 2020 Results (data cutoff: 1 August 2019) determining the safety, tolerability, and hematologic and clinical response were published in the Blood